Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. - Wikidata - awgldk - TriplyDB

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

http://www.wikidata.org/entity/Q37284812

about

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.Current evidence for histone deacetylase inhibitors in pancreatic cancer.The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Targeting histone deacetylases in pancreatic ductal adenocarcinoma.Panobinostat for the treatment of multiple myeloma.Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.

P2860

Q21198868-76D339A2-2442-4C66-87EE-834CE94E4ADC Q28076548-60A7435E-AACE-4534-97D3-0E4D6D33758D Q28534954-07A6C0F9-6D9D-47AD-8C05-293C82B799DC Q30499964-2ABA57E0-D2BF-435F-A14C-79828E2E56DB Q33409922-74BFDDC2-B46C-40A5-BF2F-F77D2E69F5FD Q34297701-CF943D89-BE7C-47C8-A4E5-A893C4EA4645 Q36616790-0975BB53-40CF-40F5-97C7-11E52EEE833C Q36709317-0423803F-3810-407E-9E74-54691917A45B Q37226511-8EAA16E9-A7C4-40BE-8D4B-B5AE00657C9B Q37310587-CA3EFAD9-05D8-4B9F-93F1-EBC0A4B6C8BF Q37992104-0404A81C-BEFB-4A52-B891-070F1D37F986 Q39576722-6BD0731A-01B6-4FAE-AA7B-F00D3A4D6216 Q39707590-9E0A042A-6BBC-4AA7-8A05-37486BD2DA0C Q51034578-0DAE29BD-F9B0-4841-99D5-76D28A41291B Q55519853-456DFE9F-7C1E-4579-A10D-8E7171C4DEE4

P2860

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

http://www.wikidata.org/entity/Q37284812

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Experimental treatment of panc ...... istone deacetylase inhibitors.

@en

Experimental treatment of panc ...... istone deacetylase inhibitors.

@nl

type

label

Experimental treatment of panc ...... istone deacetylase inhibitors.

@en

Experimental treatment of panc ...... istone deacetylase inhibitors.

@nl

prefLabel

Experimental treatment of panc ...... istone deacetylase inhibitors.

@en

Experimental treatment of panc ...... istone deacetylase inhibitors.

@nl

P1433

Q37284812-1636D486-FCB3-4D10-9904-B2CF4EDDEF74

P1476

Q37284812-2AC372B8-7CF8-441F-ABC7-31C81AD80A15

P2093

Q37284812-004E1DAE-13A7-4EB9-B50D-B08B48D5B812

Q37284812-458BFD4D-EF44-4B11-848C-B531ABB93571

Q37284812-8CF0E721-A65D-4305-9A97-BE4F0A459810

Q37284812-8EB5A9CA-1AF7-42DA-A28B-74EEC642244E

Q37284812-93D44F9A-6B41-46A8-AB22-2BB9CD82EAB0

Q37284812-A6A21EB5-D66F-4A73-B1EE-3CE8793DA20B

Q37284812-D2A213BA-63C8-443C-AEAC-293CC83AB408

Q37284812-E63CF567-A870-409C-ACAB-1ADE6BD604DC

P2860

Q37284812-0371D312-858D-41A5-A0FA-963CEC125685

Q37284812-03A7C479-CC35-4A29-BFF2-9E7C4F235189

Q37284812-0A62FE67-E22E-4D65-A5A6-3BBE71B9F35E

Q37284812-0C3617A1-377E-4603-948F-D0CD22307C0D

Q37284812-0CE31733-DFA8-42F0-8B20-4B91D463F086

Q37284812-1364CDC7-4F03-4245-A684-09A8B3B095D4

Q37284812-163684DC-91EB-464D-B1E3-AC239333CA32

Q37284812-1982FE8D-27E9-45B9-B9CB-C3769C559CE4

Q37284812-201294AA-B6E5-4368-83E2-8C635FF21C40

Q37284812-2C595939-63D4-406B-8993-BE2C09B6017F

P304

Q37284812-5405AD15-3887-40D2-94C2-4A6156D0DC90

P31

Q37284812-7975262E-D1E8-48F3-9994-A9ABCF4FF256

P356

Q37284812-AD507D38-918B-4997-8FC1-E88238A77F87

P407

Q37284812-EC1BBCCB-6469-4A10-BC85-B4BFC2C92803

P433

Q37284812-B1CF113D-3A9A-4CC8-8E93-564483743932

P478

Q37284812-0C93BF3E-4312-4B47-884A-5020F431046D

P577

Q37284812-55930E15-3E3B-42B8-8378-A753254CB8C7

P698

Q37284812-CA19A537-F5BE-4FA0-9526-89ACEDF2F7FA

P932

Q37284812-3FD4D1CC-E793-4918-A964-AF047A3E94DD

P356

P1433

World Journal of Gastroenterology

P1476

Experimental treatment of panc ...... istone deacetylase inhibitors.

@en

P2093

Christian Moebius

http://www.w3.org/2001/XMLSchema#string

Christian Wittekind

http://www.w3.org/2001/XMLSchema#string

Joachim Mossner

http://www.w3.org/2001/XMLSchema#string

Karel Caca

http://www.w3.org/2001/XMLSchema#string

Manuel Niederhagen

http://www.w3.org/2001/XMLSchema#string

Marcus Wiedmann

http://www.w3.org/2001/XMLSchema#string

Martin Haefner

http://www.w3.org/2001/XMLSchema#string

Thilo Bluethner

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylases specifically down-regulate p53-dependent gene activation

Abrogation of DUSP6 by hypermethylation in human pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cancer statistics, 2005

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.

Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A.

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

P304

3681-3692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.14.3681

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18595135

http://www.w3.org/2001/XMLSchema#string

P932

2719231

http://www.w3.org/2001/XMLSchema#string